Staar Surgical AquaFlow Glaucoma Drainage Device Approvable - FDA Panel
This article was originally published in The Gray Sheet
Executive Summary
Staar Surgical should collect expanded two-year follow-up data for patients treated with the AquaFlow collagen glaucoma drainage device as a condition of FDA approval, the agency's Ophthalmic Devices Advisory Panel recommended Nov. 8 in Gaithersburg, Maryland.
You may also be interested in...
Staar Shipping AquaFlow Glaucoma Drainage Device Following FDA Approval
Staar Surgical is shipping its AquaFlow glaucoma drainage device to 300 physcians already trained in use of the device following FDA approval, announced July 16.
Staar Shipping AquaFlow Glaucoma Drainage Device Following FDA Approval
Staar Surgical is shipping its AquaFlow glaucoma drainage device to 300 physcians already trained in use of the device following FDA approval, announced July 16.
Staar Surgical Swiss Manufacturing Facility Ready For AquaFlow Production
Staar Surgical expects to receive FDA approval of its AquaFlow extra-ocular collagen-based glaucoma drainage device in the next two-to-five weeks.